Direct-Acting Antivirals – Safety communication
October 4, 2016 – The FDA announced that a new Boxed Warning will be added to all direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, regarding the risk of hepatitis B virus (HBV) reactivation.
Download PDF
